102449-34-3

Upstream product

• 119-61-9 benzophenone 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 6071-93-8 NSC 31633 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 167108-56-7 (4-Benzhydrylidene-piperidin-1-yl)-acetic acid ethyl ester 
• 137406-16-7 3-(4-Benzhydrylidene-piperidin-1-yl)-propionic acid ethyl ester 
• 137406-18-9 4-(4-Benzhydrylidene-piperidin-1-yl)-butyric acid ethyl ester 
• 137406-19-0 5-(4-Benzhydrylidene-piperidin-1-yl)-pentanoic acid ethyl ester 
• 688304-93-0 6-(4-Benzhydrylidene-piperidin-1-yl)-hexanoic acid methyl ester 
• 50706-57-5 4-(diphenylmethylene)piperidine 
• 100169-94-6 1,1-dimethyl-4-(diphenylmethylene)piperidinium iodide 
• 6071-93-8 NSC 31633 

Relevant academic research and scientific papers

Synthesis, affinity at 5-HT(2A), 5-HT(2B) and 5-HT(2C) serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues

Cyproheptadine is a drug that shows high affinity for type 2 (5-HT2) receptors. We studied a series of compounds obtained by modification of the tricyclic system of Cyp (dibenzocycloheptadiene): 2f (thioxanthene), 2g (xanthene), 2h (dihydrodibenzocycloheptadiene), 2j (diphenyl), 2i (fluorene), and 3b (phenylmethyl). Their activities at the rat cerebral cortex 5-HT(2A) receptor were (pK(i) ± S.E.M.): 8.80 ± 0.11 (Cyp), 8.60 ± 0.07 (2f), 8.40 ± 0.02 (2g), 8.05 ± 0.03 (2h), 7.87 ± 0.12 (2j), 6.70±0.02 (2i) and 6.45±0.02 (3b); those at the rat stomach fundus 5-HT(2B) receptor (pA2±S.E.M.) were: 9.14±0.25 (Cyp), 8.49±0.07 (2F), 7.58±0.58 (2g), 7.02±0.14 (2h), 6.07±0.20 (2j), and undetectable (21, 3b); and those at the pig choroidal plexus 5-HT(2C) receptor (pK(i)±S.E.M.) were: 8.71 ± 0.08 (Cyp), 8.68 ± 0.01 (20, 8.58 ± 0.20 (2g), 7.95 ± 0.05 (2h), 7.57 ± 0.04 (2j), 6.98 ± 0.04 (2i) and 6.63 ± 0.20 (3b). The slopes did not differ significantly from unity. The compounds exhibited the same order of activities at every type of receptor, and the most active molecules presented certain steric (butterfly conformation of the tricyclic system) and electrostatic (proton affinity on the top of the central rings) patterns. It is concluded that the activity of cyproheptadine derivatives at 5-HT2 receptors is related to these molecular features, which make feasible a common disposition to interact with all three 5-HT2 subtypes.

Treatment of CNS disorders using CNS target modulators

The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.

TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS

The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.

Amphoteric drugs. I. Synthesis and antiallergic activity of [4-(diphenylmethoxy)piperidino]-, [4-(diphenylmethyl)piperazinyl]- and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives

A simple method of transforming classical antihistaminics into nonsedative antiallergic agents with strong effects in rat models is described. Various [4-(diphenylmethoxy)piperidinol - (series A), [4-(diphenylmethyl)piperazinyl]- (series B) and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives (series C) were synthesized and examined for antiallergic activities and effects on the central nervous system (CNS), in comparison with the corresponding N-methyl derivatives (1a-c). N-Alkylcarboxylic acids (5a-c) showed stronger inhibitory effects on compound 48/80-induced lethality in rats than the corresponding N-methyl derivatives (1a-c). In particular, N-alkylcarboxylic acids (5a) in series A exhibited approximately 100-fold stronger inhibitory effects than 1a, and were the least effective in prolonging the sleeping time on hexobarbital-induced anesthesia in mice in all series. As a result of chemical modification in series A, it was found that introduction of a methyl group at the para-position on one benzene ring in the (diphenylmethoxy)piperidine system effectively reduced CNS side-effects without reducing antiallergic activity. (+)-3-[4-[(4-Methylphenyl)phenylmethoxy] piperidinol propionic acid ((+)-51), an optically active isomer of 51, exhibited a stronger antiallergic effect (ED50 = 0.17 mg/kg, p.o.) than ketotifen and terfenadine in the 48 h homologous passive cutaneous anaphylaxis (PCA) test, and moreover exhibited no CNS side-effects, such as prolongation of the sleeping time on hexobarbital-induced anesthesia, at an oral dose of 30 mg/kg. Compound (+)-51 was thus proved to be a promising candidate as a nonsedative antiallergic agent.

Cyproheptadine analogues: Synthesis, antiserotoninergic activity, and structure-activity relationships

A series of cyproheptadine related compounds was synthesized and tested pharmacologically. In comparison with cyproheptadine, these compounds do not have a central ring and some contain groups other than N-methyl. Synthesis was carried out with low-valent